What Can We Help You Find?
Are you helping a loved one get the best help and treatment for a lung cancer diagnosis? Or, maybe you are facing that diagnosis yourself.
Are you looking to find a clinical trial? Do you need help paying for your treatment medications? Do you need to know what the latest research says about treatments for a specific biomarker, like ALK or EGFR? The resources presented here can help you.
Resources & Organizations
This section is where you’ll find links to everything from clinical trials to prescription assistance and much more.
All adenocarcinoma ALK+ awareness biomarker brochure caregiver support clinical trials co-pay assistance communication computed tomography (CT) scan counseling CT Scan education EGFR mutation emotional support financial assistance genomic testing KRAS latest research legal assistance lodging long-term survival lung cancer map medicaid medicare mental health help mesothelioma MRI NIH NSCLC nutrition nutrition support online community Opdivo patient support personalized medicine practical help prescription assistance radiation research advancement ROS-1 positive seniors stage IV stigma survivor transportation treatment
National Coalition For Cancer Survivorship Lilly Cares Foundation Patient Assistance Program National Cancer Institute (NCI) Novartis Patient Assistance Foundation, Inc. (PAF) Personalized Medicine for Your Lung Cancer Brochures Web MD Lung Cancer Overview Lung Cancer Circle Of Hope AACR Survivor & Patient Advocacy Program NCI Clinical Trials Search SCBN Prescription Advocacy Smart Patients Lung Cancer Community Cancer Financial Assistance Coalition Genentech Access Solutions Planning Your Doctor Visit AZ&Me Prescription Savings Program Mesothelioma Applied Research Foundation Boehringer Ingelheim Cares Foundation Patient Assistance Program International Association For The Study Of Lung Cancer Medicare.gov: Forms, Help & Resources John Wayne Cancer Foundation (JWCF) Partnership For Prescription Assistance Vanderbilt-Ingram Cancer Center: My Cancer Genome With Every Breath: A Lung Cancer Guidebook
This section presents all of the latest lung cancer research articles presented on the LCFA website. Just click on the tags that interest you.
All 5 year survival adenocarcinoma adjuvant therapy advances in lung cancer research african americans air pollution airway ALK ALK-Positive ALK+ anti-inflammatory drugs antibiotics awareness bacteria biomarker biomarker testing blood biopsy blood test BMI BRAF breast cancer vs lung cancer breath test Cancer Moonshot carcinogen chemotherapy clinical trial clinical trial navigator clinical trials combination therapy comprehensive cancer center computed tomography (CT) scan coronavirus coronavirus and lung cancer COVID-19 COVID-19 and lung cancer COVID19 CT Scans CT screening cure cancer disparity in lung cancer clinical research diversity dna sequencing Dr. Alice Berger early detection education EGFR egfr biomarker EGFR Exon 20 EGFR Exoń0-positive NSCLC EGFR mutation elderly patients equity es-sclc exon 20 positive extended stage small cell lung cancer first responders five year survival Functional Expansion of Specific T-cells analysis genetics genomic testing Health inequalites Healthcare disparity High Pd-L1 imaging imfinzi immune system immune testing immunotherapy inclusion Janet Freeman-Daily Kellie Smith keytruda KRAS KRAS clinical trial KRAS G12C KRAS G12C Mutation KRAS Inhibitor latest research LDCT liquid biopsies liquid biopsy long-term survival low dose computed tomography low dose CT scan lung cancer recurrance lung cancer research funding lung cancer risk lung cancer risks lung cancer screeing lung cancer screening lung cancer stigma lung cancer surgery Lung Cancer Vaccine lung tumor development MANAFEST medicare Medicare and lung cancer Medicare population mental health help MET MET Exon 14 skipping MET+ MET+ Exon 14 skipping molecular profiling molecular testing mortality rates Mutation-associated neoantigens mutations nasal swab NCLC Neoadjuvant neoadjuvent therapy neversmokers and lung cancer next generation sequencing NLST non-invasive non-small cell lung cancer non-smoker NSCLC NTRK NTRK fusion-positive obesity Ohio State University Opdivo p53 patient support PD-L1 PD1 pembrolizumab personalized medicine postoperative radiation postoperative radiotherapy Precision Medicine prognosis progress racial disparity and lung cancer radiation radiation therapy radon RAS research RET RET clinical trial RET Fusion-Positive NSCLC RET1 risk for lung cancer ROS-1 positive ROS1 saliva test SCLC screening screening criteria screenings second opinion seniors seniors and lung cancer small cell lung cancer smoking squamous SRT stage 4 stage iii stage IV statistics stereotactic radiotherapy stigma surgery for stage 1 lung cancer survival survival rate survivor targeted therapy Telehealth Thermal ablation thoracic surgery tobacco treatment treatment guidelines tumor resection UCLA WHO women women and lung cancer women neversmokers and lung cancer World Health Organization
Five Year Lung Cancer Survival Update Liquid Biopsy Simpler Sampling Address Disparities in Lung Cancer Screening Bone Marrow Damage Reduced for ES-SCLC Patients Imfinzi increases five year survival to 43% Role of Postoperative Radiotherapy in NSCLC Diverse Workforce in Oncology Cemiplimab-rwlc for NSCLC With High PD-L1 Immunotherapy + Chemo Boosts Response in Resectable NSCLC New NSCLC Targeted Therapy Guidelines Immuno-oncology Effectiveness in Medicare Population Immunotherapy For Early-Stage Lung Cancer Amivantamab Approved for EGFR Exon 20–Positive NSCLC Sotorasib Approved for KRAS G12C NSCLC New Treatment Approaches for Small-Cell Lung Cancer Immune-boosting drug may help before lung cancer surgery Treating NSCLC With Gene Mutations – Discussion with Dr. Gregory Masters METex14 Patients See Improved Outcomes Following Savolitinib Treatment Chromosomal Abnormality and Immunotherapy Response Why Are ‘Never-Smokers’ Getting Lung Cancer? Small-Cell Lung Cancer Guidelines Lung Cancer Rates in the United States Cancer Patients and the COVID Vaccine Expand Targeted Therapy for Lung Cancer Telehealth: Bridging the Digital Divide Is Still a Work In Progress Lung Cancer Care Disparities: Are They Truly Inclusive? Sotorasib Shows Benefits for KRAS G12C Mutation Lorlatinib Approved for ALK-Positive NSCLC Using Both, Immunotherapy and Chemotherapy Doubles Lung Cancer Survival KRAS Mutation sees Promise for New Therapies Patients With Pretreated SCLC Have Improved Outcomes IASLC Discusses Lung Cancer Care and Research Disparities Tepotinib Approved for MET+ NSCLC Breast cancer tops lung cancer as most diagnosed cancer Why are lung cancer deaths in non-smokers on the rise? Merck Pulls Keytruda for SCLC Antibody Hinders EGFR Lung Cancers Study defines SCLC subtypes How Biomarkers Impact Treatment Decisions Genetics influence SCLC risk Exploring Saliva in Early Lung Cancer Detection Racial Disparities in Lung Cancer Lung Cancer Stigma: 10 Year Study ‘But I never smoked’: Never smokers and lung cancer COVID-19 and Lung Cancer: First Liquid Biopsy Approved for Multiple Genes Lung Cancer Screenings Are Down Tagrisso as Adjuvant Therapy for NSCLC Approved Trailblazer KRAS treatment filed with FDA KRAS G12C Treatment Breakthrough Treatments for Lung Cancer Newly Available in 2020 Aggressive Lung Cancer and new target Lung Cancer Surgery: Women fare better than men KRAS G12C mutation drug shows ‘positive’ Phase II results Targeted therapy effective for RET Treatment Changes Due to COVID-19 Combination EGFR Therapy Boosts Survival in Early Lung Cancer KRAS drug tackles 32% of Lung Cancers RET Fusion-Positive NSCLC Treatment Gets Approval Pan-Tumor Liquid Biopsy Gets Approval MET-targeting lung cancer drug gets quick review RET inhibitor for lung cancer Racial disparities in lung cancer FDA Accepts NDA for Trilaciclib for SCLC Lung Cancer Mortality Rates Drop Sharply Improved Progression-Free Survival Treatments Expand for EGFR-positive NSCLC FDA Approves Small Cell Lung Cancer (SCLC) Treatment COVID19 severity and lung cancer Tagrisso cuts lung cancer recurrence by 83% Combination Therapy Aproved for First-Line Treatment NSCLC with MET exon 14 skipping Treatment Approved End the Debate on Biomarker Testing for NSCLC African Americans and Lung Cancer Screening Lung Cancer Treatment Progress Over the Last Decade Testing Patients with Lung Cancer for COVID-19 Conducting Clinical Trials During Coronavirus Pandemic Does Delaying ALK+ Treatment Impact Survival? Durvalumab Approved for SCLC African American Lung Cancer Patients less likely to receive lung cancer imaging Coronavirus and Cancer: 1-2 Punch When Cancer And Coronavirus Collide Biomarker Testing and CT Screening Vital for Lung Cancer Faulty Immune System May Lead to Lung Cancer Is Lung Cancer Related to Air Pollution? Acquired Drug Resistance Strategy Death Rate Drop: Lung Cancer Research Key Small Cell Lung Cancer (SCLC) Treatment Refusal for Small Cell Lung Cancer How Are We Failing Lung Cancer Patients so Miserably? Liquid Biopsies and NSCLC Inadequate Lung Cancer Screening Guidelines for First Responders Liquid Biopsies and Molecular Testing in Lung Cancer Nasal-Swab Lung Cancer Test Tecentriq: IMpower-ing results MET Treatment Gets Breakthrough Designation RET Drug Shrinks Tumors in Trial I/O Imfinzi prolongs survival TMB and Lung Cancer Treatment KRAS Treatment Shows Promise Entrectinib approved for ROS1 and NTRK Liquid Biopsy: Are We Ready for a ‘Blood-First’ Approach? Long-Term Survival for EGFR+ Blood Test Could Identify Potential Lung Cancer Markers Clinical Trial Navigators FDA approves Keytruda for SCLC The Relationship Between Air Pollution and Lung Cancer in Nonsmokers What good is it to be able to cure cancer if we routinely fail to deliver that cure? Artificial intelligence and cancer Know Your Genes: Testing for Genomic Mutations in Lung Cancer Lung Cancer Stigma: Not Just the Patient’s Problem Could invigorating the immune system prevent lung cancer? Precision of Liquid Biopsy and Osimertinib Resistance Current Open Clinical Trials FDA approves new treatment for extensive-stage small cell lung cancer El Paso County Public Health advises people to test homes for radon Antibiotics or anti-inflammatory drugs may help combat lung cancer New Treatment Options for ROS1, BRAF, and NTRK Alterations in NSCLC Molecular profiling could catch lung cancer early and lead to new treatments New Protein Found Linked to Lung Cancer Treatment Resistance What happens when the doctor blames you for your own cancer? Patients now living a median 6.8 years after stage IV ALK+ lung cancer diagnosis Lung Cancer Deaths are 28 Percent Lower in California First-Line Immunotherapy Combo Fails to Improve Survival in Lung Cancer Trial FDA Approves Atezolizumab Combination Policy changes needed for access to lung cancer treatments New DNA sequencing test credited with saving his life Personalized Medicine for NTRK Fusion-Positive Solid Tumors Women with lung cancer live longer than men After Decades, New Standard of Care in Small Cell Lung Cancer Can body fluids help spot lung cancer? Air Pollution Increases Lung Cancer Risk in Nonsmokers Safe, Effective Treatment for Early-Stage Lung Cancer Anti-cancer treatment designed to lower risk of cancer’s return Combination Therapy Study Reduces Risk of Death by Half Broad-Based Testing: Will it Improve Survival? FDA Approves Opdivo for Small Cell Lung Cancer Researchers Use Big Data to Predict Immunotherapy Responses Liquid Biopsy Could Ease the Way to Immunotherapy for Lung Cancer Lung cancer mortality rates among women projected to increase Could a Simple Blood Test Detect Early-Stage Lung Cancer? Blood test improves lung cancer risk assessment for smokers Combination Therapy New Standard of Care for Squamous NSCLC New Combination Therapy Clinical Trial for UCLA New Noninvasive Method for Lung Cancer Screening Why non-smokers are getting lung cancer Lung Cancer Research gains $6,000,000 for 2019 Combination Therapy for Small Cell Lung Cancer Study: Keytruda better than chemo against advanced lung cancer New research finds lung cancer risk drops substantially within five years of quitting smoking Lung cancer rates in young women raise concerns Low Lung Cancer Screening Rate Immunotherapy Combination Increases Lung Cancer Survival Testing for all lung cancer mutations at once found cost effective Attention: Extensive-stage small cell lung cancer patients New liquid biopsy-based cancer model reveals data on deadly lung cancer What Is EGFR and How Does It Relate to Lung Cancer? Immuno therapy scores big win against lung cancer in study NSCLC with EGFR mutations gets new first-line treatment approved by FDA ALK-positive non-small cell lung cancer gets boost from Lorlatinib Scientists identify 170 potential lung cancer drug targets Dr. Kellie Smith: Neoadjuvant PD-1 Blockade in Resectable Lung Cancer Lung Cancer Patients Live Longer With Immune Therapy Outpatient Immunotherapy for Lung Cancer Tecentriq plus chemo cut risk of death in type of lung cancer UCLA Opens New Trial for Stage IV NSCLC Patients FDA Approves 4-Week Nivolumab Dosing Schedule Inhalation to be Used in New Trial for Second-Line NSCLC Patients Merck’s Ace Keytruda Impresses Again, Stuns in Phase III Lung Cancer Trial FDA Expands Afatinib’s Approval for Lung Cancer Many Elderly Lung Cancer Patients Receive No Treatment Seeking Consensus Amid Abundant New Lung Cancer Data Targeted Therapies Convey Survival Benefit in Patients With Lung Cancer The Biggest Cancer News Of 2017? ‘CAR-T Cells, Hands Down’ Will Immunotherapy And Radiation Be Combined In Lung Cancer Treatment? It’s Crucial That Patients Identify The Mutations Driving Their Lung Cancers UCLA Lung Cancer Screening and Early Detection Active Therapeutic Thoracic Trials – December 2017 FDA grants approval for in vitro diagnostic Dr. Garon on Immunotherapy as Salvage Treatment for Advanced Lung Cancer Liquid Biopsies: A Lung Cancer Game-Changer? Active Therapeutic Thoracic Trials – November 2017 Tumor Mutation Burden Shows Promise as a Response Biomarker in Small Cell Lung Cancer LCFA trio contribute to ‘cancer interception’ project Alecensa Approved as First-Line Treatment Immunotherapy for Lung Cancers: First-Line and Beyond iSABR Trial for Early-Stage, Unresectable NSCLC Now Open Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib Clinical Trial News from UCLA We’re more likely to get cancer than to get married. Opdivo Improves Long-Term Survival in Advanced Lung Cancer Lung Cancer: Is Your Doctor Screening You for the Best Treatment? Merck’s immunotherapy, chemo mix shows extended lung cancer gains Blood tumor markers may warn when lung cancer patients are progressing Keytruda Shows Promise in Small Cell Lung Cancer Changing Treatment Paradigm for ALK-Positive Lung Cancer Blood test can predict early lung cancer prognosis Blocking Post-MI Inflammation Tied to Fewer Lung Cancer Deaths Blood Test Finds Cancer Before Symptoms Start Newly Diagnosed with Lung Cancer? Get a Second Opinion Too Many Drugs in Too Many Trials and Not Enough Patients? Lung cancer diagnosis increases suicide risk by 420% New Trial for NSCLC Patients with no Previous Immunotherapy Opens Alecensa Gets Priority Review For Initial Treatment Of People With ALK-Positive Lung Cancer Changes to Improve Usability of ClinicalTrials.gov New CDC Report Shows Deaths from Cancer Higher in Rural America Full FDA Approval Granted for Anti-Cancer Drug Targeting EGFR Protein Found in Lung Cancer and Mesothelioma FDA Approves Tafinlar, Mekinist Combo to Treat BRAF V600E Non-Small Cell Lung Cancer With Patients Reporting Symptoms Using Web Tool, Survival Improves Combined immune checkpoint blockade shows promise for small cell lung cancer ASCO 2017: Alectinib halts lung cancer growth more than a year longer than crizotinib Lab on a Chip Outlines New Liquid Biopsy Technology Improved Survival Using Imfinzi In Sequential Treatment in NSCLC FDA Approves Keytruda Combo for Lung Cancer FDA Grants Lorlatinib Breakthrough Designation for NSCLC DNA-based test can spot cancer recurrence a year before conventional scans Pre-surgical Immunotherapy Trial to Open at UCLA Main Campus AACR Annual Meeting 2017: Panel Discusses the Affordable Care Act AACR Annual Meeting 2017: Immunotherapy Provides Long-lasting Responses to Certain Cancer Types Phase III Study Shows Genentech’s Alecensa® Was Superior to Crizotinib in a Specific Type of Lung Cancer Drug Offers Some Hope for a Deadly Lung Cancer ‘Bad luck’ mutations increase cancer risk more than behavior, study says Immunotherapy Trial for EGFR Mutation Positive Patients to Expand Enrollment Advice From Patients On A Study’s Design Makes For Better Science Trial for Patients Doing Well on Nivolumab Expands to UCLA Stand Up To Cancer Ushers In New Approach to Research Advanced NSCLC Patients Live Longer When Treated, but Proportion of Untreated Patients Rising Multimillion Dollar Grant Awarded from the National Cancer Institute for Translational Research at UCLA and in TRIO-US Personalized Medicine Impacting Study Conduct Immunotherapy Agent Improved Quality of Life in Lung Cancer Study No Personalized Treatments for 20% of Newly Diagnosed Living Under a Cloud: Examining Air Pollution’s Effects on Lung Cancer Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival AstraZeneca pill slashes lung cancer progression in study New application of existing drug offers personalized therapy for lung cancer Safety and Efficacy of ABRAXANE® for Challenging Patient Populations KEYTRUDA Data in Small Cell Lung Cancer and Mesothelioma Microsoft Shows Searches Can Boost Early Detection of Lung Cancer Liquid Biopsy — “Powerful Tool” In Precision Lung Cancer Therapy, Study Shows Alectinib and ALK-Positive Non-Small Cell Lung Cancer Blue Ribbon Panel Presentation to National Cancer Advisory Board for Cancer Moonshot
In this section, you’ll find interviews with the key opinion leaders in lung cancer research on the topics pertinent to lung cancer patients, survivors and caregivers.
All ALK+ awareness biomarker caregiver support clinical trials comprehensive cancer center CT Scan driver mutation early detection education EGFR mutation family funding genomic testing grants investigator latest research long-term survival non-smoker NSCLC oncologist Opdivo patient support PD-L1 personalized medicine prognosis research advancement research grants ROS-1 positive Scans screening second opinion statistics stigma support targeted therapy thoracic oncologist treatment
Advances in Lung Cancer Research Advocacy – Lung Cancer Foundation of America (LCFA) Biopsies and Tissue Sample Size Everyday Stories and Realities of Lung Cancer Findings from the National Lung Screening Trial Genetic Mutations in Lung Cancer How To Get Your Tumor Tested LCFA Grants: How They Help Using Early Detection to Improve Patient Outcomes What Does Dr. Donington Research? Why Is Targeted Therapy Important